Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lumos Diagnostics Holdings Ltd. ( (AU:LDX) ) has provided an update.
Lumos Diagnostics has secured a A$5.0 million loan facility from major shareholders Tenmile Ventures and Ryder Capital to support its efforts in obtaining a CLIA waiver for its FebriDx® product from the FDA. This financial move is part of a broader strategy to maintain momentum towards commercialization while minimizing equity dilution. Additionally, Lumos has entered into a significant distribution agreement with PHASE Scientific, valued at US$317 million, contingent upon achieving the CLIA waiver. This agreement marks one of the largest distribution deals for an ASX-listed diagnostics company and is expected to provide substantial funding alongside the loan facility to meet Lumos’s working capital needs.
More about Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Ltd. is a leader in rapid, point-of-care diagnostic technologies. The company focuses on developing diagnostic solutions that provide quick and accurate results, catering primarily to the healthcare industry. Its flagship product, FebriDx®, is designed to assist in the detection of febrile respiratory infections.
Average Trading Volume: 1,036,112
Technical Sentiment Signal: Sell
Current Market Cap: A$21.71M
Find detailed analytics on LDX stock on TipRanks’ Stock Analysis page.